Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment

Completed

• Conditions: Schizophrenia

• Registration Number: NCT00758251
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of this study is to assess severity of illness in schizophrenia patients in routine clinical practice at the time of entry in the study and after the treatment with Seroquel XR for 8 weeks.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-09
• Study First Submitted: 2008-09-23
• Study First Submitted QC: 2008-09-23
• Study First Posted: 2008-09-25
• Primary Completion: 2009-03
• Study Completion: 2009-03
• Status Verified: 2010-12
• Last Update Submitted: 2010-12-08
• Last Update Posted: 2010-12-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Adult patients with Schizophrenia prescribed on Seroquel XR according to the approved product information before inclusion in this non-interventional study
• Signed and dated Patient Informed Consent (ICF)

Exclusion Criteria

• Hypersensitivity to the active substance or to any of the excipients of Seroquel XR

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in CGI scores and BPRS comparing visits 1 and 3.	twice with 4 week interval

Secondary Outcome Measures

Name	Time	Method
To evaluate compliance to therapy	twice with 4 week interval

Trial Locations

Locations (2)

Research Site; 🇱🇻 Valmiera, Latvia

Research SIte; 🇱🇻 Cesis, Latvia